Retatrutide FDA Approval 2026: Timeline, Current Status, and What to Expect

# Retatrutide FDA Approval 2026: Timeline, Status, and What to Expect > **Quick answer: Is retatrutide FDA approved?** No. As of 2026, retatrutide is **not FDA approved** and cannot be legally prescribed for weight loss in the United States. Eli Lilly submitted its New Drug Application (NDA) in late 2025 and the drug remains under FDA review. Based on standard Priority Review timelines, a potential FDA decision is projected for **late 2026 to early 2027** — no official PDUFA approval date has been publicly confirmed. Retatrutide — Eli Lilly's next-generation triple agonist weight loss drug — has generated significant interest in the medical and patient community. Searches for "retatrutide FDA approval 2026," "when will retatrutide be FDA approved," and "retatrutide release date" have surged over the past year. This article provides a comprehensive update on where approval currently stands, what Phase 3 data shows, and what patients and clinicians should know heading into the second half of 2026. ## What Is Retatrutide? Retatrutide (development code: LY3437943) is a once-weekly injectable peptide developed by Eli Lilly. Unlike semaglutide (a GLP-1 receptor agonist) or tirzepatide (a dual GLP-1/GIP agonist), retatrutide is a **triple agonist** that activates: - **GLP-1 (glucagon-like peptide-1)** receptors — reduces appetite and slows gastric emptying - **GIP (glucose-dependent insulinotropic polypeptide)** receptors — enhances insulin response and fat metabolism - **Glucagon receptors** — increases energy expenditure and fat oxidation This triple mechanism is designed to produce greater and more sustained weight reduction than existing GLP-1 or dual agonists. ## Retatrutide Phase 2 Results: The Benchmark Before discussing the 2026 FDA approval timeline, it is worth reviewing the Phase 2 data that set expectations: **TRIUMPH Phase 2 Trial (New England Journal of Medicine, 2023):** - Participants: Adults with obesity (BMI 30 or above) without diabetes - Duration: 48 weeks - Top dose (12 mg weekly): **24.2% mean body weight reduction** - 8 mg weekly: approximately 22.8% weight reduction - Placebo: 2.1% weight reduction These results far exceeded semaglutide (~15%) and tirzepatide (~21%) in comparable contexts, establishing retatrutide as the most potent weight loss injectable studied at that time. ## Retatrutide Phase 3 Trials: TRIUMPH Program Eli Lilly's Phase 3 development program is called **TRIUMPH** (Triple Receptor Agonist Investigation for Outcomes in patients with Metabolic disorders: Providing Health). The program includes multiple trials: ### TRIUMPH-1 (Obesity Without Diabetes) - Population: Adults with BMI of 30 or above, or 27 with weight-related comorbidities - Primary endpoint: Percentage body weight change at 72 weeks - Status: Completed enrollment; results under regulatory review ### TRIUMPH-2 (Type 2 Diabetes) - Population: Adults with obesity and type 2 diabetes - Primary endpoints: HbA1c reduction and body weight change - Status: Completed ### TRIUMPH-3 and TRIUMPH-4 - Extended cardiovascular outcomes and additional population studies - Status: Ongoing; long-term follow-up data collection ### TRIUMPH CVOT (Cardiovascular Outcomes Trial) - Evaluating cardiovascular risk reduction - Longer timeline: full results expected 2027-2028 ## Retatrutide FDA Approval Timeline: 2026 Status ### NDA Submission Eli Lilly submitted a **New Drug Application (NDA) to the FDA** in late 2025, based on accumulated Phase 3 data from the TRIUMPH program. This is a critical milestone in the approval process. ### FDA Review Pathway Retatrutide is expected to receive **Priority Review** designation from the FDA, given the serious public health need for effective obesity treatments. Under Priority Review: - Standard review window: 10 months - Priority review window: **6 months** from NDA acceptance If FDA accepted the NDA in Q4 2025 under Priority Review, a **PDUFA (Prescription Drug User Fee Act) action date** in the range of **mid-to-late 2026** is possible. However, complete response letters, advisory committee meetings, or label negotiations could extend this timeline. ### Current Status as of March 2026 As of March 2026, retatrutide remains **under FDA review** and has not been approved. The most realistic scenarios based on disclosed timelines: - **Optimistic:** FDA approval late 2026 (Q3-Q4) - **Base case:** FDA approval H1 2027 - **Conservative:** Extended review pushing into late 2027 The exact PDUFA date has not been publicly confirmed as of this writing. ## How Retatrutide Compares to Approved Alternatives | Drug | Mechanism | Max Dose | Avg Weight Loss | Status | |------|-----------|----------|----------------|--------| | Semaglutide (Wegovy) | GLP-1 | 2.4 mg/week | ~15% | FDA approved (2021) | | Tirzepatide (Zepbound) | GLP-1 + GIP | 15 mg/week | ~21% | FDA approved (2023) | | Retatrutide | GLP-1 + GIP + Glucagon | 12 mg/week | ~24% | Under FDA review | The data suggests retatrutide could establish a new efficacy benchmark in approved weight loss medications if its Phase 3 results confirm Phase 2 findings. ## What Patients and Clinicians Should Know ### Retatrutide Is Not Yet Available for Prescription As of early 2026, retatrutide is **not FDA approved** and cannot be legally prescribed for obesity treatment in the United States. Compounded peptide versions marketed as "research use only" are not equivalent to the pharmaceutical product in clinical development and should not be used as substitutes. ### Side Effect Profile from Phase 2 Phase 2 data showed a safety profile broadly similar to other GLP-1 based medications: - Nausea, vomiting, diarrhea (most common, dose-dependent) - Constipation - Decreased appetite - Injection site reactions The glucagon receptor component adds differentiation: slightly higher rates of initial nausea and potential for greater energy expenditure effects compared to tirzepatide. ### Who May Benefit Most Retatrutide may be particularly relevant for: - Patients who did not achieve adequate weight loss on semaglutide - Patients looking to step up from tirzepatide for greater efficacy - Those with insulin resistance who may benefit from the glucagon component's metabolic effects - Clinics building comprehensive metabolic programs alongside [NAD+ therapies](/guides/how-to-store-nad-powder-reconstituted-nad-guide) and other longevity interventions ## The Broader GLP-1 Landscape in 2026 The FDA approved tirzepatide (Zepbound) for obesity in late 2023, and the market has since expanded with multiple GLP-1 programs under development. Retatrutide enters a competitive landscape but has differentiated efficacy data: - **Semaglutide** remains the most widely prescribed, with strong cardiovascular outcome data - **Tirzepatide** demonstrated superior weight loss versus semaglutide in SURMOUNT trials - **Retatrutide** targets an additional glucagon receptor, offering potential advantages in fat oxidation and long-term metabolic improvement For clinicians building [GLP-1 treatment programs](/guides/glp1-medications-comparison-chart-guide), staying updated on the retatrutide approval timeline is important for patient counseling and practice planning. ## Summary Retatrutide represents the most promising next generation in GLP-1 based obesity pharmacology. Its triple agonist mechanism — targeting GLP-1, GIP, and glucagon receptors — produced approximately 24% weight loss in Phase 2 trials, surpassing both semaglutide and tirzepatide. As of March 2026, retatrutide is under FDA review following NDA submission. A potential approval date in late 2026 or early 2027 is possible based on Priority Review timelines, though final regulatory decisions depend on the full Phase 3 data package and FDA evaluation. For patients currently on [semaglutide](/guides/semaglutide-dosing-schedule-week-by-week-guide) or [tirzepatide](/guides/tirzepatide-vs-semaglutide-comparison), retatrutide may offer a future step-up option for those seeking greater weight reduction outcomes. This page will be updated as FDA decisions, PDUFA dates, and Phase 3 data become available.